Androgen News and Research

RSS

Obesity and infertility in women

Obese women have alterations in their ovaries which might be responsible for an egg's inability to make an embryo, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Mar 2009

Proepithelin encourages cell growth and migration in prostate cancer

Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells.

26 Feb 2009

Medivation announces new positive efficacy data from trial of MDV3100 in Castration-resistant prostate cancer

Medivation, Inc. has announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients.

25 Feb 2009

Virotherapy treatment kills prostate cancer cells

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer.

21 Jan 2009

Scientists visualize the mechanism of synthesizing estrogen

The molecular details of Aromatase, the key enzyme required for the body to make estrogen, are no longer a mystery thanks to the structural biology work done by the Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in Buffalo, New York.

7 Jan 2009

Why prostate cancer patients fail hormone deprivation therapy

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.

1 Jan 2009

Having dense breasts increases breast cancer risk

Having dense breasts - areas that show up light on a mammogram - is strongly associated with increased breast cancer risk, but "why" remains to be answered.

14 Dec 2008

New recommendations on late-onset hypogonadism

The January issue of European Urology, the official journal of the European Association of Urology published by Elsevier, will feature new recommendations on late-onset hypogonadism (LOH), recently formulated by major scientific organizations.

5 Dec 2008

Stereotypical imperfections offer health benefits when it comes to bodies

Having an imperfect body may come with some substantial benefits for some women, according to a new article in the December issue of Current Anthropology.

3 Dec 2008

Degarelix prostate cancer drug makes testosterone levels fall dramatically and quickly

More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.

3 Dec 2008

Breast and prostate cancer treatment may result in bone loss

A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss.

16 Nov 2008

Testosterone effective treatment for low libido in postmenopausal women

An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women.

7 Nov 2008

New genetic test for baldness

Pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC, today unveiled the next generation of its genetic screening test for male pattern baldness. The HairDX test is available immediately thru qualified physicians' offices.

28 Oct 2008

Transsexual genes identified

Australian scientists believe they have identified a significant link between a gene involved in testosterone and male-to-female transsexualism.

27 Oct 2008

Prostate cancer genes behave like those in embryo

Gene activity in prostate cancer is reminiscent of that in the developing fetal prostate, providing further evidence that all cancers are not equal, Johns Hopkins researchers report. The finding could help scientists investigate how to manipulate the genetic program to fight a disease whose biology remains poorly understood despite more than half a century of investigation.

16 Sep 2008

Why hormone therapy for prostate cancer fails

Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.

21 Aug 2008

New way to treat advanced prostate cancer, potentially more effective, fewer side effects

Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.

29 Jul 2008

Hormone deprivation therapy - used for prostate cancer - may cause recall and concentration problems

A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients--such as in the ability to recall and concentrate.

28 Jul 2008

Androgen deprivation therapy does not improve survival for elderly men with localized prostate cancer

A therapy that involves depriving the prostate gland the male hormone androgen is not associated with improved survival for elderly men with localized prostate cancer, compared to conservative management of the disease, according to a study in the July 9 issue of JAMA, the Journal of the American Medical Association.

9 Jul 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008